
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Netupitant,Dexamethasone,Palonosetron
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Recipient : Helsinn Advanced Synthesis
Deal Size : Undisclosed
Deal Type : Agreement
Helsinn, Chugai renew partnership to sell AKYNZEO® in UK and Ireland
Details : The agreement aims to commercialise Akynzeo (combination of netupitant-palonosetron), for the treatment of chemotherapy-induced nausea and vomiting (CINV) in adult patients, in UK and Ireland.
Product Name : Akynzeo
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 12, 2024
Lead Product(s) : Netupitant,Dexamethasone,Palonosetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Recipient : Helsinn Advanced Synthesis
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Netupitant
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Imperial College Healthcare NHS Trust
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Netupitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gallbladder Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 27, 2020
Lead Product(s) : Netupitant
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Imperial College Healthcare NHS Trust
Deal Size : Inapplicable
Deal Type : Inapplicable

Study of CH5132799 Administered Orally in Patients With Advanced Solid Tumors
Details : CH5132799 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 18, 2010
